دورية أكاديمية
[Current treatment of AL amyloidosis].
| العنوان: | [Current treatment of AL amyloidosis]. |
|---|---|
| المؤلفون: | Desport, Estelle, Moumas, Eric, Abraham, Julie, Delbès, Sébastien, Lacotte-Thierry, Laurence, Touchard, Guy, Fermand, Jean-Paul, Bridoux, Franck, Jaccard, Arnaud |
| المساهمون: | Service de néphrologie - hémodialyse et transplantation rénale, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service d'hématologie clinique et de thérapie cellulaire CHU Saint-Antoine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Service d'Hématologie clinique et thérapie cellulaire CHU Limoges, CHU Limoges |
| المصدر: | ISSN: 1769-7255 ; Néphrologie et Thérapeutique ; https://hal.archives-ouvertes.fr/hal-00945696Test ; Néphrologie et Thérapeutique, Elsevier Masson, 2011, 7 (6), pp.467-73. ⟨10.1016/j.nephro.2011.02.003⟩. |
| بيانات النشر: | HAL CCSD Elsevier Masson |
| سنة النشر: | 2011 |
| المجموعة: | Archive ouverte HAL (Hyper Article en Ligne, CCSD - Centre pour la Communication Scientifique Directe) |
| مصطلحات موضوعية: | MESH: Amyloid, MESH: Amyloidosis, MESH: Immunoglobulin Light Chains, MESH: Kaplan-Meier Estimate, MESH: Kidney Failure, Chronic, MESH: Kidney Transplantation, MESH: Melphalan, MESH: Natriuretic Peptide, Brain, MESH: Paraproteinemias, MESH: Paraproteins, MESH: Peptide Fragments, MESH: Prognosis, MESH: Biological Markers, MESH: Pyrazines, MESH: Randomized Controlled Trials as Topic, MESH: Renal Dialysis, MESH: Thalidomide, MESH: Boronic Acids, MESH: Cardiomyopathies, MESH: Consensus Development Conferences as Topic, MESH: Dexamethasone, MESH: Drug Therapy, Combination, MESH: Heart Transplantation, MESH: Humans, [SDV.IMM]Life Sciences [q-bio]/Immunology |
| الوصف: | International audience ; Systemic AL amyloidosis is a rare complication of monoclonal gammopathies. Renal manifestations are frequent, mostly characterized by heavy proteinuria, with nephrotic syndrome and renal failure in more than half of the patients at diagnosis. Without treatment, median survival does not exceed 12 months. Amyloid heart disease and diffusion of amyloid deposits are associated with reduced survival. Treatment of systemic AL amyloidosis has been profoundly modified with the introduction of international criteria for the definition of organ involvement and hematologic response, and with the use of sensitive tests for the measurement of serum-free light chain levels. Melphalan plus dexamethasone is now established as the gold standard for first line treatment of systemic AL, with similar efficacy and reduced treatment-related mortality compared to high-dose therapy. Modern chemotherapy regimens, based on the use of novel agents such as bortezomib and lenalidomide, might further improve patient survival. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | French |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/21497573; hal-00945696; https://hal.archives-ouvertes.fr/hal-00945696Test; PUBMED: 21497573 |
| DOI: | 10.1016/j.nephro.2011.02.003 |
| الإتاحة: | https://doi.org/10.1016/j.nephro.2011.02.003Test https://hal.archives-ouvertes.fr/hal-00945696Test |
| رقم الانضمام: | edsbas.60246BC2 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.nephro.2011.02.003 |
|---|